| __timestamp | Neurocrine Biosciences, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 14400000 | 9216000000 |
| Thursday, January 1, 2015 | 33800000 | 8296000000 |
| Friday, January 1, 2016 | 35900000 | 10044000000 |
| Sunday, January 1, 2017 | 1254000 | 11560000000 |
| Monday, January 1, 2018 | 4889000 | 10558000000 |
| Tuesday, January 1, 2019 | 7400000 | 9351000000 |
| Wednesday, January 1, 2020 | 10100000 | 8933000000 |
| Friday, January 1, 2021 | 14300000 | 8284000000 |
| Saturday, January 1, 2022 | 23200000 | 7952000000 |
| Sunday, January 1, 2023 | 39700000 | 8200000000 |
| Monday, January 1, 2024 | 34000000 | 8480000000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue for two prominent companies: Teva Pharmaceutical Industries Limited and Neurocrine Biosciences, Inc., from 2014 to 2023.
Teva, a global leader in generic medicines, consistently reported a high cost of revenue, peaking at approximately $11.56 billion in 2017. However, a noticeable decline of around 31% was observed by 2022, reflecting strategic cost management or market challenges.
Conversely, Neurocrine Biosciences, a biopharmaceutical company specializing in neurological and endocrine-related disorders, showed a different trajectory. Starting with a modest cost of revenue, it surged by over 2,600% from 2014 to 2023, reaching nearly $39.7 million. This growth underscores Neurocrine's expanding market presence and investment in innovation.
This comparative insight highlights the diverse financial strategies within the pharmaceutical sector, offering valuable perspectives for market analysis.
Cost of Revenue Trends: Zoetis Inc. vs Teva Pharmaceutical Industries Limited
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Corcept Therapeutics Incorporated
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Cytokinetics, Incorporated
Cost Insights: Breaking Down Teva Pharmaceutical Industries Limited and Alkermes plc's Expenses
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Geron Corporation
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored